P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimensJosep Tabernero, Angela Capriati, Gunnar Folprecht et al.|Annals of Oncology|2020Cited by 5